The current NAMSW market cap is 754.6M. The company's latest EPS is EUR -2.1455 and P/E is -9.08.
Quarter End | |
---|---|
EUR (€) | |
Total Revenue | |
Operating Income | |
Net Income |
Year End December 30 2023 | 2023 |
---|---|
EUR (€) | |
Total Revenue | 14.09M |
Operating Income | -182.69M |
Net Income | -176.94M |
Quarter End | |
---|---|
EUR (€) | |
Total Assets | |
Total Liabilities | |
Total Equity |
Year End December 30 2023 | 2023 |
---|---|
EUR (€) | |
Total Assets | 347.1M |
Total Liabilities | 58.7M |
Total Equity | 288.39M |
Market Cap | 754.6M |
Price to Earnings Ratio | -9.08 |
Price to Sales Ratio | 113.98 |
Price to Cash Ratio | 4.72 |
Price to Book Ratio | 5.57 |
Dividend Yield | - |
Shares Outstanding | 82.47M |
Average Volume (1 week) | 0 |
Average Volume (1 Month) | 0 |
52 Week Change | - |
52 Week High | - |
52 Week Low | - |
Spread (Intraday) | 2.15k (100%) |
Company Name | NewAmsterdam Pharma Company NV |
Address |
gooimeer 2-35 naarden, north holland 1411 DC |
Website | https://www.newamsterdampharma.com |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.